FDA approves 1st chronic HDV treatment Hepcludex to reduce virus levels and improve liver function in adults with hepatitis delta virus.

In phase III study, patients taking bulevirtide had ALT normalization and steep drops in H ...

Chronic HDV occurs only with HBV and confers markedly higher risks of rapid progression, cirrhosis, liver failure, and ...

The FDA approved Hepcludex injection for the treatment of chronic hepatitis D infection in adults without cirrhosis or with ...

More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA due to manufacturing and delivery concerns, the treatment has since redeemed itself by scoring a green ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated ...

Fifteen years ago, doctors in Europe noticed a remarkable thing happening in people with chronic hepatitis B infections. When patients went off their medications, the virus started to come back—and ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral ...

Jody Baron and Gabi Fragiadakis discover why some people with chronic Hepatitis B are cured after they're taken off of ...

Europe is facing a growing chronic liver disease threat, according to a new series published in The Lancet Regional ...